ARDX Ardelyx Inc

Ardelyx Inc is a clinical stage biopharmaceutical company. It engages in the discovery, development and commercialization of non-systemic, molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal and metabolic diseases.

As of 06/24/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/19/2014
Outstanding shares:  144,598,863
Average volume:  3,450,793
Market cap:   $86,658,099
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BN89V40
Valuation   (See tab for details)
PE ratio:   -0.56
PB ratio:   1.26
PS ratio:   21.76
Return on equity:   -238.48%
Net income %:   -3,843.36%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy